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Objectives: Spinocerebellar ataxia type 3/Machado–Joseph disease (SCA3/MJD) is 
a polyglutamine disorder with no current disease-modifying treatment. Conformational 
changes in mutant ataxin-3 trigger different pathogenic cascades, including reactive 
oxygen species (ROS) generation; however, the clinical relevance of oxidative stress ele-
ments as peripheral biomarkers of SCA3/MJD remains unknown. We aimed to evaluate 
ROS production and antioxidant defense capacity in symptomatic and presymptomatic 
SCA3/MJD individuals and correlate these markers with clinical and molecular data with 
the goal of assessing their properties as disease biomarkers.
Methods: Molecularly confirmed SCA3/MJD carriers and controls were included in 
an exploratory case–control study. Serum ROS, measured by 2′,7′-dichlorofluorescein 
diacetate (DCFH-DA) as well as superoxide dismutase (SOD) and glutathione peroxidase 
(GSH-Px) antioxidant enzyme activities, levels were assessed.
results: Fifty-eight early/moderate stage symptomatic SCA3/MJD, 12 presymptomatic 
SCA3/MJD, and 47 control individuals were assessed. The DCFH-DA levels in the 
symptomatic group were 152.82  nmol/mg of protein [95% confidence interval (CI), 
82.57–223.08, p < 0.001] higher than in the control and 243.80 nmol/mg of protein 
(95% CI, 130.64–356.96, p < 0.001) higher than in the presymptomatic group. The SOD 
activity in the symptomatic group was 3 U/mg of protein (95% CI, 0.015–6.00, p = 0.048) 
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lower than in the presymptomatic group. The GSH-Px activity in the symptomatic group 
was 13.96 U/mg of protein (95% CI, 5.90–22.03, p < 0.001) lower than in the control 
group and 20.52 U/mg of protein (95% CI, 6.79–34.24, p < 0.001) lower than in the 
presymptomatic group and was inversely correlated with the neurological examination 
score for spinocerebellar ataxias (R = −0.309, p = 0.049).
conclusion: Early/moderate stage SCA3/MJD patients presented a decreased antioxi-
dant capacity and increased ROS generation. GSH-Px activity was the most promising 
oxidative stress disease biomarker in SCA3/MJD. Further longitudinal studies are nec-
essary to identify both the roles of redox parameters in SCA3/MJD pathophysiology and 
as surrogate outcomes for clinical trials.
Keywords: spinocerebellar ataxia type 3, Machado–Joseph disease, oxidative stress, reactive oxygen species, 
polyglutamine disorders
inTrODUcTiOn
Machado–Joseph disease (MJD), also referred to as spinocer-
ebellar ataxia type 3 (SCA3/MJD), is an autosomal dominant 
neurodegenerative disorder caused by a CAG repeat expansion 
(CAGexp) at ATXN3, the gene that codes for ataxin-3. SCA3/
MJD is part of the so-called group of polyglutamine (PolyQ) 
disorders (1); it is the most common form of SCA worldwide (2), 
with a minimal prevalence of 6:100,000 in Rio Grande do Sul, 
Brazil (3, 4).
Spinocerebellar ataxia type 3/Machado–Joseph disease onset 
typically occurs at approximately 32–40 years of age (2, 3, 5, 6). 
Gait ataxia is the main neurological sign; however, ataxia sub-
sequently affects speech, swallowing, and limb coordination. 
Pyramidal, extrapyramidal, and peripheral nerve findings also 
occur during the disease course (1). The median survival time 
after onset is 21 years (7).
Expansion of the polyQ tract induces conformational changes 
in ataxin-3, which affects many properties of the protein, includ-
ing stability and degradation (8), subcellular localization (9), 
molecular interactions with other proteins (10–12), and propen-
sity to aggregate (9).
Aggregates of mutant polyQ proteins may be taken up by 
neuronal mitochondria, which leads to disturbances in the mem-
brane potential and a subsequent increase in reactive oxygen spe-
cies (ROS) production (13). Recent studies have demonstrated an 
imbalance between the ROS production and antioxidant defense 
capacity in patients and cellular models of SCA3/MJD, linking 
these abnormalities to the neurodegenerative process of the 
disease (12–15). In addition, oxidative stress increases ataxin-3 
nuclear localization (16), a crucial step for SCA3/MJD in  vivo 
phenotypic manifestation (17).
Natural history (NH) studies with well-validated SCA scales 
have indicated a very slow progression of ataxic and non-ataxic 
signs in SCA3/MJD (18–20) and have stressed the need for large 
sample sizes to test disease-modifying therapies in future rand-
omized clinical trials (RCTs) (18–24). Surrogate biomarkers may 
hasten RCT and drug discoveries for SCA3/MJD, a disorder with 
no modifying treatment to date. The potential clinical relevance 
of oxidative stress elements as peripheral biomarkers of SCA3/
MJD in patients has rarely been addressed (12, 15).
Considering the hypothesis of an oxidative stress imbal-
ance in SCA3/MJD that may precede disease onset, we aimed 
to evaluate the peripheral ROS production and antioxidant 
defense capacity in symptomatic and presymptomatic SCA3/
MJD individuals and a control population. We also evaluated 
the relationship of these markers with clinical and molecu-
lar data, with the goal to assess their properties as disease 
biomarkers.
MaTerials anD MeThODs
Population, Design, and eligibility criteria
Symptomatic patients with a molecular diagnosis of SCA3/
MJD or asymptomatic individuals with a normal neurological 
examination at 50% risk of SCA3/MJD on the basis of an affected 
first-degree relative who were seeking presymptomatic testing 
were recruited for this single-site, exploratory, case–control study 
at the Neurogenetics outpatients clinic, Hospital de Clinicas de 
Porto Alegre, from May 2011 to July 2013.
The data for symptomatic patients were collected during the 
baseline assessments of a RCT, in which a disease duration of 
more than 10 years and an inability to walk independently (canes, 
sticks, or walkers were allowed) were exclusion criteria (23). The 
control group consisted of previously at-risk individuals who did 
not carry CAGexp at ATXN3 plus healthy unrelated individuals 
with age, gender, and environmental characteristics similar to 
symptomatic individuals. Thyroid, renal, or hepatic disorders or 
a history of other significant neurological or systemic medical 
disorders were also exclusion criteria.
Molecular and clinical evaluations
The ATXN3 expanded region was analyzed as previously described 
(25). The Neurological Examination Score for Spinocerebellar 
Ataxias (NESSCA) (26) and the Scale for the Assessment and 
Rating of Ataxia (SARA) (27) were performed in all symptomatic 
individuals. The disease duration and age at disease onset of first 
symptom were provided by the patients and/or relatives. The 
median estimated age at onset of the presymptomatic group was 
calculated with the individuals’ current age and CAGexp length in 
ATXN3, as previously reported (28).






Mean (sD) Mean (sD) Mean (sD) p
N 47 58 12
Age (years) 40.7 (13.3) 40.6 (9.6) 32.4 (8.1) 0.053a
Female sex (n, %) 27 (57.4) 29 (48.3) 7 (58.3) 0.596b
Age at onset (years) – 34.5 (9.1) –
Disease duration (years) – 5.3 (2.5) –
CAGexp length – 75.4 (3.2) 73.5 (3.0) 0.071c
NESSCA – 14.2 (4.8) –
SARA – 9.7 (4.1) –
Predicted disease onset 
(years)




NESSCA, Neurological Examination Score for Spinocerebellar Ataxias; SARA,  
Scale for the Assessment and Rating of Ataxia; SCA3/MJD, spinocerebellar ataxia  
type 3/Machado–Joseph disease.
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sample collection
Biological material collection was performed between 8 a.m. and 
4 p.m. under fasting conditions. Serum was obtained via blood 
centrifugation at 6,000 × g for 5 min, frozen immediately, and 
stored at −80°C until analysis.
redox assays
All samples and standards were measured in triplicate with vari-
ation coefficients <10%.
ROS Levels
To assess the ROS levels, 2′,7′-dichlorofluorescein diacetate 
(DCFH-DA) (Sigma-Aldrich, St. Louis, MO, USA) was used as a 
probe (29). An aliquot of the serum sample (60 µl) was incubated 
with DCFH-DA (final concentration 100 µM) at 37°C, in the dark, 
for 30 min. DCFH oxidation was measured fluorimetrically, using 
488 nm excitation and 525 nm emission wave lengths. A standard 
curve using standard DCF (Sigma-Aldrich, St. Louis, MO, USA) 
(0.25–10 mM) was performed in parallel with the samples, and 
the results were expressed as nanomoles per milligram protein.
Antioxidant Enzyme Activities
The superoxide dismutase (SOD) (EC 1.15.1.1) activity was 
assessed by quantifying the inhibition of superoxide-dependent 
auto-oxidation of epinephrine and analyzing the absorbance of 
the samples at 480 nm. In microplate wells that contained serum 
samples (30 µl–60 µg of protein), 140 µl of glycine buffer (final 
concentration 50  mM; pH 10.2) and 10  µl of catalase (Sigma-
Aldrich, St. Louis, MO, USA) (EC 1.11.1.6) (final concentration 
10 µM) were added. In standard wells, only 180 µl of glycine buffer 
(final concentration 50 mM; pH 10.2) and 10 µl of catalase were 
added (final concentration 10 µM). The reaction was initiated by 
the addition of 10 µl of epinephrine (Sigma-Aldrich, St. Louis, 
MO, USA) (final concentration 60  mM) in all wells. The zero 
time absorbance was obtained at 480 nm, followed by recording 
the absorbance after 10 min at 32°C. The SOD activity unit was 
defined as the required enzyme amount to inhibit epinephrine 
oxidation by 50%. Data were expressed as units per milligram 
protein (29).
The glutathione peroxidase (GSH-Px, EC 1.11.1.9) activ-
ity was measured in a 96-well plate according to the method 
described by Wendel (30) using tert-butyl hydroperoxide as the 
substrate (Sigma-Aldrich, St. Louis, MO, USA). Nicotinamide 
adenine dinucleotide phosphate (NADPH) disappearance was 
monitored spectrophotometrically at 340 nm in a medium that 
contained (final concentrations): 2 mM of reduced glutathione 
(GSH), 0.15  U/ml glutathione reductase (GR) (EC 1.8.1.7), 
0.4 mM azide, 0.5 mM tert-butyl hydroperoxide, and 0.1 mM 
NADPH plus serum sample (40  µl–80  µg of protein). One 
GSH-Px unit was defined as 1 µmol of NADPH consumed per 
minute, and the specific activity is represented as units per mil-
ligram of protein.
statistical analysis
All investigated variables showed a normal distribution via a one-
sample Kolmogorov–Smirnov test. The baseline characteristics 
among the groups were compared with ANOVA, independent 
samples t-test or chi-square test. The ROS levels and antioxidant 
enzyme activities among the groups were compared using the 
Generalized Linear Model (GLM) corrected for age. Differences 
between the specific groups in the GLM were assessed using Wald 
chi-square with Bonferroni correction for multiple comparisons. 
Correlations were performed with the Pearson correlation test, 
followed by a linear regression model when required. Statistical 
significance was defined as p < 0.05.




where x is the sample value (raw score), μ is the population mean, 
and σ is the standard deviation of the population. The absolute 
value of Ζ represents the distance between the raw score and the 
population mean in units of SD (31).
ethics
The study was approved by the Ethics in Research Committee 
of our institution (register number 10-513). Written informed 
consent was obtained from all subjects prior to participation.
resUlTs
Fifty-eight individuals comprised the early/moderate stage 
symptomatic SCA3/MJD group, 12 individuals comprised the 
asymptomatic SCA3/MJD group, and 47 individuals comprised 
the healthy control group (9 related and 38 unrelated to the SCA3/
MJD individuals). The clinical and demographic characteristics 
are described in Table 1.
The serum DCFH-DA levels (p < 0.001) and the SOD (p = 0.026) 
and GSH-Px (p <  0.001) activities were different among some 
of the groups (Figures  1 and 2, Table S1 in Supplementary 
Material).
The levels of the ROS marker DCFH-DA in the symptomatic 
group were 152.82 nmol/mg of protein [95% confidence interval 
(CI), 82.57–223.08, p <  0.001] higher than in the control and 
FigUre 1 | Redox parameters in healthy controls, symptomatic, and presymptomatic SCA3/MJD individuals. (a) ROS levels, (B) SOD activity, (c) GSH-Px activity 
and (D) Correlation between GSH-Px and NESSCA. Values are presented as the means, and error bars represent standard error; *p < 0.05 and ***p < 0.001. 
GSH-Px, glutathione peroxidase; NESSCA, Neurological Examination Score for Spinocerebellar Ataxias; ROS, reactive oxygen species; SCA3/MJD, spinocerebellar 
ataxia type 3/Machado–Joseph disease; SOD, superoxide dismutase.
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243.80 nmol/mg of protein (95% CI, 130.64–356.96, p < 0.001) 
higher than in the presymptomatic group. The DCFH-DA levels 
were similar between the presymptomatic SCA3/MJD and con-
trol individuals (90.97 nmol/mg of protein, 95% CI, −21.83 to 
203.79, p = 0.161). Refer to Figures 1A and 2A.
The SOD activity was 3  U SOD/mg of protein (95% CI, 
0.015–6.00, p = 0.048) lower in the symptomatic than that of the 
presymptomatic SCA3/MJD group. There were no differences 
in the SOD activity between the symptomatic SCA3/MJD and 
control groups (1.51 U SOD/mg of protein, 95% CI, −0.37 to 3.39, 
p = 0.165) or the presymptomatic SCA3/MJD and control groups 
(1.49 U SOD/mg of protein, 95% CI, −1.51 to 4.50, p = 0.700). 
Refer to Figures 1B and 2A.
The GSH-Px activity in the symptomatic SCA3/MJD was 13.96 
U GSH-Px/mg of protein (95% CI, 5.90–22.03, p < 0.001) lower 
than in the control and 20.52  U GSH-Px/mg of protein (95% 
CI, 6.79–34.24, p <  0.001) lower than in the presymptomatic 
SCA3/MJD group. The GSH-Px activity was similar between 
the presymptomatic SCA3/MJD and control groups (6.55  U 
GSH-Px/mg of protein, 95% CI, −7.19 to 20.30, p = 0.762). Refer 
to Figures 1C and 2A.
Oxidative stress Parameter correlations 
with clinical and Molecular Findings
The DCFH-DA levels and SOD activity did not correlate with 
the clinical features or molecular data in the symptomatic group 
(Figure S1 in Supplementary Material). The GSH-Px activity 
exhibited an inverse correlation with the NESSCA severity in 
the symptomatic group (R = −0.309, p =  0.049, Figure  1D), 
i.e., lower levels of GSP-Px activity were identified in the patients 
with more severe disease. No significant correlations of oxida-
tive stress markers with predicted age of onset or CAG expansion 
length were identified in the presymptomatic SCA3/MJD group 
(p > 0.05 for all comparisons, Figure S2 in Supplementary Material).
DiscUssiOn
This study evaluated redox parameters in a representative sample 
of symptomatic SCA3/MJD patients and presymptomatic carri-
ers. The ROS marker DCFH-DA was higher in the symptomatic 
SCA3/MJD individuals; the activity of the antioxidant enzyme 
GSH-Px was lower in the symptomatic SCA3/MJD group and 
FigUre 2 | Representative cluster of the redox analyses in healthy controls (n = 35), symptomatic (n = 35), and presymptomatic (n = 10) SCA3/MJD individuals. 
The results were analyzed as Ζ-score values. Ζ is negative when the sample value is below the population mean and positive when it is above the mean. (a) Each 
square represents one individual. DCFH-DA, 2′,7′-dichlorofluorescein diacetate; GSH-Px, glutathione peroxidase; SCA3/MJD, spinocerebellar ataxia type 3/
Machado–Joseph disease; SOD, superoxide dismutase. (B) Color key of row z-score.
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was associated with the disease severity; the presymptomatic 
carriers presented a higher activity of the antioxidant enzyme 
SOD than the symptomatic SCA3/MJD patients. Overall, these 
results indicate a pro-oxidative stress state in the early/moderate 
stages of SCA3/MJD and a potential antioxidant defense response 
in presymptomatic carriers.
In the present study, we identified higher ROS in the symp-
tomatic SCA3/MJD patients measured by the DCFH-DA serum 
levels. The lack of correlations between the DCFH-DA levels and 
clinical or molecular data should be considered in the perspective 
of a peripheral marker for a disease that mainly affects the CNS. 
Nevertheless, our results differed from a clearly underpowered 
6de Assis et al. Oxidative Stress in SCA3/MJD
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case–control study (seven SCA3/MJD and seven control indi-
viduals) that reported no differences in the DCFH-DA levels 
between groups (15).
Oxidative stress damage has been involved in several path-
ological processes that affect various organs and tissues. Spe-
cifically, the brain is particularly vulnerable as denoted by many 
neurodegenerative diseases of which oxidative stress has been 
implicated in the pathogenesis (16, 32). As previously stated, 
neuronal mitochondria function may be directly impaired by 
polyQ aggregates, which may lead to increased ROS generation 
(13). Alternatively or simultaneously, ROS may increase in SCA3/
MJD as a result of a direct failure of antioxidant enzymes.
In our study, we identified higher SOD activity in the presymp-
tomatic than early/moderate stages of symptomatic SCA3/MJD 
individuals. Furthermore, the GSH-Px activity was lower in the 
symptomatic SCA3/MJD group, and these lower levels were cor-
related with greater disease severity as measured via the ataxia 
and non-ataxia sign scale NESSCA. Pacheco et al. (15) identified 
similar results, in which the thiol levels, an indirect measure of 
GSH-Px activity, were lower in SCA3/MJD patient sera. Therefore, 
the GSH-Px activity was the most promising oxidative stress dis-
ease biomarker in SCA3/MJD, and our results strengthened the 
findings of previous indirect studies on the GSH-Px activity and 
present novel data that correlated this marker with disease severity.
According to our data, significant oxidative stress was only 
present after disease onset, and we speculate whether a failure/
exhaustion in antioxidant defense mechanisms (depicted by an 
increased activity of SOD in the presymptomatic stages) may 
play a role in disease onset. Higher peripheral SOD activity in 
presymptomatic individuals than controls was a remarkable find-
ing that departs from the previous scenarios. The hypothesis of an 
antioxidant defense response present in presymptomatic carriers 
is appealing, particularly in face of preliminary evidence that sug-
gests alterations in other pathways are present in the preclinical 
phases of this disease (33). Nevertheless, it remains necessary to 
determine whether high SOD activity in the prodromal phases 
represents a phenomenon common to other tissues, such as 
the CNS. However, we emphasize that experimental evidence 
indicates a link between oxidative stress and SCA3/MJD pathol-
ogy. The brain has a cellular defense system against oxidative 
stress, which includes high levels of several antioxidant enzymes, 
including SOD, GSH-Px, GSH reductase, and catalase (14). GSH 
plays predominant roles in the removal of excess H2O2 from 
the brain (14), as well as SOD in the removal of O2− (32). Lower 
GSH levels and decreased activity of GSH reductase, catalase, 
and SOD were previously identified in mutant SCA3/MJD cell 
lines compared with wild-type cells, which suggests that mutant 
ataxin-3 may influence the activity of enzymatic components to 
efficiently remove both O2− and H2O2 (14). Ataxin-3 binds to target 
gene promoters and modulates transcription by interacting with 
transcriptional regulators. During oxidative stress, ataxin-3 and 
forkhead box O (FOXO) transcription factor FOXO4 translocate 
to the nucleus, concomitantly bind to the SOD2 gene promoter 
and increase the expression of the antioxidant enzyme SOD2. 
Mutant ataxin-3 has a reduced capability to activate FOXO4-
mediated SOD2 expression (12). The downregulation of SOD2 
was confirmed in pons tissue and lymphoblastoid cell lines of 
SCA3/MJD patients. In SCA3/MJD patient lymphoblastoid cell 
lines, an impairment to upregulate SOD2 expression in associa-
tion with a significant increase in ROS formation and cytotoxicity 
were reported, which suggests that a decreased antioxidant capac-
ity and increased susceptibility toward oxidative stress contribute 
to neuronal cell death (12).
The general characteristics of the recruited sample were 
similar to the local SCA3/MJD population (4), such as the gender 
proportion, age at onset, and range of CAGexp. Despite several 
strengths, our study has several limitations. As we designed an 
exploratory case–control study, no primary outcome was elected, 
and no sample size calculation or study power determinations 
were performed. We conducted an exploratory study because 
of the lack of data on redox markers in SCA3/MJD patients and 
we would not have available the number of presymptomatic 
individuals necessary for an adequately powered study. As our 
sample sizes are one of the largest on biomarker studies of this 
disorder, the number of recruited individuals represents one of 
the study’s merits.
In conclusion, early/moderate stage symptomatic SCA3/
MJD patients presented a similar peripheral redox profile to the 
previously reported SCA3/MJD cellular models: a decreased anti-
oxidant capacity and an increased production of ROS. Additional 
collaborative studies with larger sample sizes of presymptomatic 
individuals and a prospective design may help to uncover the NH 
of these markers and their roles as surrogate (disease or treat-
ment) biomarkers for future clinical trials, as well as understand 
the association between the failure of the antioxidant defense and 
disease onset and its potential therapeutic implications.
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FigUre s1 | Correlations of redox parameters with clinical and molecular data in 
the symptomatic SCA3/MJD group. *p < 0.05. DCFH, 2′,7′-dichlorofluorescein 
diacetate; GSH-Px, glutathione peroxidase; NESSCA, Neurological Examination 
Score for Spinocerebellar Ataxias; SARA, Scale for the Assessment and Rating 
of Ataxia; SCA3/MJD, spinocerebellar ataxia type 3/Machado–Joseph disease; 
SOD, superoxide dismutase.
FigUre s2 | Correlations of redox parameters with clinical and molecular data in 
the presymptomatic SCA3/MJD group. Predicted time to onset (in years) was 
calculated with the formula: current age—predicted age of onset [according to 
Ref. (28)]. DCFH, 2′,7′-dichlorofluorescein diacetate; GSH-Px, glutathione 
peroxidase; SCA3/MJD, spinocerebellar ataxia type 3/Machado–Joseph disease; 
SOD, superoxide dismutase.
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